Author: Smead Capital Management

Academia vs. The Real World – Part 1

In preparation for a talk, I began to review Sir John Templeton’s track record with the Templeton Growth Fund (TEPLX), which he managed from 1954 to 1991. At the age of 34, with a father that broke into the investment business in 1980, I was very aware of Templeton’s success in his career, but unaware of how the results came to his clients. What you walk away with after reviewing his track record is the knowledge that very few people in our industry (particularly academics) are conscious of what it took to produce that success. After Templeton, we also reviewed Sequoia Fund (SEQUX) from inception to date. We walked away thinking that the ride that the investors had with these vehicles wasn’t the most important part of the experience, it was the results. Academia says otherwise. We will unpack this.

⟶ Keep Reading

Barron’s: Bill Smead on Long-Run Stock Prices

U.S. Markets Are Closed but the Selloff Continues By Teresa Rivas For more information go to www.barrons.com. The information contained in this article represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.

⟶ Keep Reading

CNBC Squawk Box: Bill Smead on 5-10 Year Outlook

Bill Smead expects a strong economy for the next 5-10 years Hosted by Becky Quick and Joe Kernen For more information go to www.cnbc.com. Stocks mentioned: TGT, HD The information contained in this tv appearance represents SCM’s opinions, and should not be construed as personalized

⟶ Keep Reading

Barron’s: Bill Smead on Tech Behavior

The Dow Is Soaring 158 Points Because the Pie Looks Bigger By Teresa Rivas For more information go to www.barrons.com. Stocks mentioned: FB The information contained in this article represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance

⟶ Keep Reading

CNN Business: Cole Smead, CFA on the Next Bear Market

Stock market freakout: Wall Street bets the boom may be over By Matt Egan For more information go to www.cnn.com. The information contained in this article represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no guarantee

⟶ Keep Reading

Well Known Facts Can Hurt You

Our long-time readers are aware that we analyze the U.S. stock market through the prism of what we call “well-known facts.” A well-known fact is a body of economic information which is pretty much known to all market participants and has been acted on by almost everyone with available capital. Former Intel CEO Andy Grove use to say, “when everyone knows something is so, nobody’s knows nothin’.” Today there are several well-known facts which we believe are leading investors down a destructive path.

⟶ Keep Reading

CNBC Closing Bell: Cole Smead, CFA on Market Plays

Where to buy as stocks sell off Hosted by Wilfred Frost and Morgan Brennan Stocks mentioned: DISCA, NVR, BAC The information contained in this tv appearance represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no guarantee

⟶ Keep Reading

Barron’s: Bill Smead on Amgen

This Biotech Stock Is a Remedy for Tougher Times By Al Root For more information go to www.barrons.com. Stocks mentioned: AMGN The information contained in this article represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no

⟶ Keep Reading
Scroll to Top